While there are limited data linking CDKN2A/B loss to chordomagenesis, studies in other solid tumors, such as glioma, have suggested that CDKN2A/B deletion may confer resistance to certain therapies. The gene discussed is CDKN2A; the disease is central nervous system cancer.